On October 22, Kodiak Sciences Inc. fell 5.01% in Regular Trading, trading at $88.04 per share, with turnover of $55.33 million.
The main public catalyst still being discussed is the company’s previously disclosed positive Phase 3 wet AMD progress, alongside a large share purchase by director Felix Baker, even as the stock pulled back during the session.
Earlier disclosures indicated that Zenkuda and tabirafusp-ted met primary endpoints in Phase 3 wet AMD studies, with non-inferiority in vision gains versus aflibercept over the first year. The company has said it plans to submit certain ophthalmology program data in the fourth quarter. Separately, Felix Baker, through Baker Bros. Advisors, bought about $157 million of stock at around $80.85 per share, lifting the affiliated holding to roughly 35%. The combination of late-stage clinical progress and substantial insider-linked buying has continued to shape trading attention, though it did not prevent this session’s decline.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments